Spots Global Cancer Trial Database for Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma
Official Title: An Open-label, Single Arm, Multi-center Pilot Study of Programmed Cell Death Protein 1 Antibody (PD-1# Toripalimab Combined With Sorafenib in Patients With Advanced Hepatocellular Carcinoma Cannot Undergo Surgical Resection and TACE
Study ID: NCT04926532
Conditions
Study Description
Brief Summary: Toripalimab is a programmed cell death protein 1 antibody.This is an open-label, single arm, multi-center exploratory study.The objective of this study is to evaluate the efficacy and safety of therapy with toripalimab and sorafenib in patients with advanced stage hepatocellular carcinoma.
Detailed Description: The objective of this study is to evaluate the efficacy and safety of therapy with toripalimab and sorafenib in patients with advanced stage hepatocellular carcinoma.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Zhongshan Hospital, Shanghai, , China
Contact Details
Name: Jian Zhou, Professor
Affiliation: Shanghai Zhongshan Hospital
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
